tert-butyl 4-hydroxy-4-[2-(hydroxymethyl)-5-methylphenyl]piperidine-1-carboxylate | 909034-71-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl 4-hydroxy-4-[2-(hydroxymethyl)-5-methylphenyl]piperidine-1-carboxylate
• CAS: 909034-71-5
• 化学式: C₁₈H₂₇NO₄
• 分子量: 321.417
• InChiKey: ZXXWEGGIOQGERZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  70
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-hydroxy-4-[2-(hydroxymethyl)-5-methylphenyl]piperidine-1-carboxylate 在 甲基磺酰氯 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以43 %的产率得到tert-butyl 6-methyl-1'H,3H-spiro[2-benzofuran-1,4'-piperidine]-1'-carboxylate
  参考文献：
  名称：

  [EN] SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME
  [FR] DÉRIVÉS DE SPIRO PIPÉRIDINE UTILISÉS EN TANT QU'INHIBITEURS DE APOL1 ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  The disclosure provides at least one compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of Formula I, tautomers thereof, deuterated derivatives of those compounds or tautomers, and pharmaceutically acceptable salts of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in treating APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and/or non-diabetic kidney disease (NDKD).

  公开号：

  WO2023154314A1
• 作为产物：
  描述：

  (2-溴-4-甲基苯基)甲醇 、 N-叔丁氧羰基-4-哌啶酮 在 正丁基锂 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 以45 %的产率得到tert-butyl 4-hydroxy-4-[2-(hydroxymethyl)-5-methylphenyl]piperidine-1-carboxylate
  参考文献：
  名称：

  [EN] SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME
  [FR] DÉRIVÉS DE SPIRO PIPÉRIDINE UTILISÉS EN TANT QU'INHIBITEURS DE APOL1 ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  The disclosure provides at least one compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of Formula I, tautomers thereof, deuterated derivatives of those compounds or tautomers, and pharmaceutically acceptable salts of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in treating APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and/or non-diabetic kidney disease (NDKD).

  公开号：

  WO2023154314A1

文献信息

• 1,2,4-Triazole Derivatives and Their Use as Oxytocin Antagonists
  申请人：Brown Alan Daniel

  公开号：US20110092529A1

  公开（公告）日：2011-04-21

  The present invention relates to a class of substituted triazoles of formula (I) with activity as oxytocin antagonists, uses thereof, processes for the preparation thereof and compositions containing said inhibitors. These inhibitors have utility in a variety of therapeutic areas including sexual dysfunction, particularly premature ejaculation (P.E.).

  本发明涉及一类具有氧催产素拮抗活性的取代三唑的化合物(I)，其用途、制备方法以及含有该抑制剂的组合物。这些抑制剂在多种治疗领域中具有实用价值，包括性功能障碍，特别是早泄(P.E.)。
• WO2006/92731
  申请人：——

  公开号：——

  公开（公告）日：——
• [EN] SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME<br/>[FR] DÉRIVÉS DE SPIRO PIPÉRIDINE UTILISÉS EN TANT QU'INHIBITEURS DE APOL1 ET LEURS PROCÉDÉS D'UTILISATION
  申请人：[en]VERTEX PHARMACEUTICALS INCORPORATED

  公开号：WO2023154314A1

  公开（公告）日：2023-08-17

  The disclosure provides at least one compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of Formula I, tautomers thereof, deuterated derivatives of those compounds or tautomers, and pharmaceutically acceptable salts of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in treating APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and/or non-diabetic kidney disease (NDKD).